Infinity Bio is pleased to announce the release of their MuSIGHT™ mouse autoantibody reactome service offering. Defining an ...
Q4 2024 Earnings Call Transcript February 28, 2025 Operator: Good day, and thank you for standing by. Welcome to the Nautilus ...
The proteoCHIP LF 48 is a state-of-the-art label-free single-cell proteomics sample preparation solution. Designed for ...
Despite a delay in the platform launch, Nautilus Biotechnology Inc (NAUT) showcases advancements in proteomics and maintains a strong cash position.
Seattle's Nautilus Biotechnology is laying off 16% of workforce, and plans to release its commercial platform in late 2026.
SEATTLE, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial ...
BOSTON and SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a clinical-stage precision medicine company seeking to unlock the proteome to advance ...
During myogenic differentiation the cellular architecture and proteome of muscle stem cells and myoblasts undergo extensive remodeling. These molecular processes are only partially understood and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback